Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-02-27 · accession 0001628280-26-014326 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2026-02-27+ | ARQT | Matsuda Masaru | See Remarks | S - Sale | $26.03 | -12.1K | 136.9K | -8% | -$313.9K |
| D | 2026-03-03 | 2026-02-27 | ARQT | Matsuda Masaru | See Remarks | A - Grant | $0.00 | +37.0K | 147.0K | +34% | $0 |
| D | 2026-03-03 | 2026-02-27 | ARQT | Matsuda Masaru | See Remarks | A - Grant | $0.00 | +97.0K | 97.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | S | D | 1,987 | $25.70 | 136,932 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-02 | S | D | 6,553 | $25.16 | 137,125 | D | — | — | (F4) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-02-27 | S | D | 3,325 | $27.95 | 143,678 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-27 | A | A | 37,000 | $0.00 | 147,003 | D | — | — | |
| 5 | Common | Common Stock | 2026-03-02 | S | D | 193 | $25.91 | 136,932 | D | — | — | (F5) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.71 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 6 | Derivative | Stock Option (right to buy) | 2026-02-27 | A | A | 97,000 | $0.00 | 97,000 | D | $26.97 · — to 2036-02-27 | 97,000 Common Stock | (F6) 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |